Keywords: idec, begins, phii, rheumatoid, arthritis, trial, pharmaceuticals

IDEC begins PhII rheumatoid arthritis trial

Article | 10 August 2000

IDEC Pharmaceuticals has initiated a Phase II clinical trial of thefirm's primatized, non-depleting anti-CD4 monoclonal antibody, clenoliximab (IDEC-151), in rheumatoid ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Drugs

methotrexate

Trexall

Go to drug listing